
...

By Hollie Silverman
News Editor
0
Share
Newsweek is a Trust Project member
See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.
The Food and Drug Administration (FDA) issued new draft guidance for the development of non-opioid treatments for chronic pain on Wednesday.
The draft, titled Development of Non-Opioid Analgesics for Chronic Pain, outlines steps to creating and seeking alternative chronic pain treatments amid the opioid epidemic, specifically the development of non-opioid analgesic products.
Analgesics are medications, like ibuprofen and acetominophen, that relieve pain by reducing inflammation or blocking pain signals in the nervous system.
Read More
Map Shows States Expecting Warmest Temperatures Next Week3 min read
![]()
Alex Jones Takes $1.4 Billion Sandy Hook Appeal to Supreme Court6 min read

Trump Loyalists Pam Bondi, Kash Patel Face Lawsuit Over FBI Purge5 min read

"Despite recent declines, opioids remain commonly prescribed to about 1 in 5 U.S. adults who live with chronic pain as effective alternatives are limited," a press release from the FDA said.
Newsweek has reached out to the American Medical Association on Wednesday via email for comment.
Why It Matters
The guidance arrived amid federal efforts to reduce reliance on opioids for pain management and expand treatment options after the agency approved a first-in-class non-opioid analgesic for acute pain earlier this year.
The Department of Health and Human Services (HHS), which oversees the FDA, has made several changes under Secretary Robert F. Kennedy Jr.'s leadership, with many criticizing the most recent move by the department to change guidance on vaccines.
Kennedy has spoken openly about his use of heroin, an opioid. Heroin, as well as pain relievers like oxycodone, hydrocodone and oxymorphone, are described as semi-synthetic opioids because they're made in laboratories by chemically processing natural opioids.

...
What To Know
The draft guidance outlined FDA recommendations on design elements for Phase 3 trials of prescription non-opioid analgesics intended to treat chronic pain, including considerations for trial populations, endpoints and safety assessments.
The document explicitly linked the guidance to the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act, which directed the FDA to issue or update guidance to help address challenges to developing non-opioid products to treat pain.
The SUPPORT Act, made law in 2018, sought to increase the capacity of Medicaid providers to deliver substance use disorder treatment or recovery services. It saw millions of dollars in grants to multiple states to combat substance use disorder and opioid misuse.
Journavx (suzetrigine) 50 mg oral tablets, the first-in-class non-opioid analgesic for moderate to severe acute pain, was approved by the FDA in January 2025, marking a regulatory milestone that the agency said expanded non-opioid treatment options for acute pain.
The Centers for Disease Control and Prevention (CDC) updated opioid-prescribing guidance in 2022 to emphasize that nonopioid therapies were preferred for many types of pain, reinforcing federal clinical guidance toward using multimodal, nonopioid strategies when appropriate.
What People Are Saying
FDA Commissioner Marty Makary, M.D., M.P.H., in a press release on Wednesday: "America's opioid crisis is not over. We must stay vigilant to address this longstanding problem in new ways. Physicians need more alternatives to opioid medications for patients suffering from chronic pain. FDA can help by providing clear guidance like this, which makes regulatory pathways more predictable for innovators and drug developers, enabling effective, lower-risk therapies to quickly reach the millions of Americans living with chronic pain."
The U.S. Food and Drug Administration (FDA), in a press release on Wednesday: "The FDA's broader strategy to address the opioid crisis includes requiring safety labeling changes for opioid pain drugs (e.g., OxyContin) to better reflect current evidence; enhancing enforcement around the importation and sale of illegal opioid products; and facilitating the development of non-opioid alternatives."
What Happens Next
The FDA will accept public comment on the draft guidance for the next 60 days. The agency may revise the guidance based on feedback from sponsors, clinicians, patient groups and other stakeholders before issuing a final guidance.
The draft guidance could shape clinical trial designs, labeling considerations and FDA review expectations for future prescription non-opioid analgesics seeking approval for chronic pain indications, potentially influencing investment and development priorities in the pharmaceutical industry.
Update 9/10/25, 1:50 p.m. ET: This story has been updated with more information.
View 0 Comments
Submit Correction
View Editorial & AI Guidelines